The progression of ER+ luminal breast cancers is associated with development of endocrine resistance, a phenomenon only in part related to dysregulation of ER and its pathway and, particularly, to the acquisition of activating mutations in ESR1 gene observed in about 18% of tumors with acquired resistance to aromatase inhibitors [172]. The gene discussed is CYP19A1; the disease is breast cancer.